AASLD/INASL: Updates on Diagnosis and Treatment of Hepatic Encephalopathy

Nov 06 2026

Convention Center: Bluebird Ballroom 2GH

2:00 PM - 3:00 PM

World Class Speakers

Description

Hepatic encephalopathy (HE) remains a major challenge in the management of chronic liver disease, with significant implications for patient outcomes and quality of life. Faculty explore core topics: the phenotypic spectrum of HE; how infections, sarcopenia, and gut microbiome dynamics drive recurrence; and emerging pharmacological strategies beyond traditional therapies for HE.

Presentations

2:00 PM - 2:12 PM

Convention Center - Bluebird Ballroom 2GH

Epidemiology and Phenotypes of Hepatic Encephalopathy

SUNIL TANEJA, MBBS, MD, DM | Presenter

2:12 PM - 2:24 PM

Convention Center - Bluebird Ballroom 2GH

Infections, Sarcopenia, and the Gut Microbiome: Key Drivers of Hepatic Encephalopathy Recurrence

Barjesh C Sharma, MD | Presenter

2:24 PM - 2:36 PM

Convention Center - Bluebird Ballroom 2GH

Beyond Lactulose and Rifaximin: Emerging Pharmacological Approaches to Hepatic Encephalopathy and Quality of Life

Patricia Bloom, MD | Presenter

2:36 PM - 2:48 PM

Convention Center - Bluebird Ballroom 2GH

Understanding Artificial Intelligence and Machine Learning in Enhancing Hepatic Encephalopathy Diagnosis: Predicting Episodes and Guiding Personalized Treatment

Christina N Awad, MD | Presenter

Objectives

Evaluate the emerging pharmacological approaches beyond traditional treatments and their impact on the quality of life for persons with hepatic encephalopathy (HE).
Summarize the key epidemiological data and phenotypic characteristics of hepatic encephalopathy.
Identify and discuss how infections, sarcopenia, and the gut microbiome influence the recurrence of hepatic encephalopathy.
Review the potential roles of artificial intelligence and machine learning in enhancing the diagnosis of HE and personalizing treatment strategies.